ProCE Banner Activity

Atezolizumab + nab-Paclitaxel in Previously Untreated Advanced Metastatic TNBC: Updated OS Analysis of Phase III IMpassion130

Slideset Download
Conference Coverage
In patients with advanced PD-L1–positive TNBC, first-line atezolizumab + nab-paclitaxel was associated with a 7 month OS benefit compared with placebo + nab-paclitaxel.

Released: June 06, 2019

Expiration: June 04, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro